DOI . ORG {}

Analyzed Page
Matching Content Categories
CMS
Monthly Traffic Estimate
How Does Doi.org Make Money
Keywords
Topics
Questions
Schema
External Links
Analytics And Tracking
Libraries
Hosting Providers
CDN Services

We began analyzing https://link.springer.com/article/10.1007/s00262-005-0110-x, but it redirected us to https://link.springer.com/article/10.1007/s00262-005-0110-x. The analysis below is for the second page.

Title[redir]:
Tumor escape mechanisms in prostate cancer | Cancer Immunology, Immunotherapy
Description:
Numerous immunotherapy trials have been carried out in prostate cancer (PC) patients, with induction of antigen-specific T cells in some cases. Despite this capability, limited success is seen in terms of tumor regression or survival. In this review, we discuss the evidence for tumor escape strategies that may contribute to vaccine failure in the setting of PC. These include defects in antigen presentation, production of immunosuppressive substances, induction of T cell death, T cell receptor dysfunction, and the presence of tolerogenic dendritic cells and regulatory T cells inside prostate tumors. It is clear that novel strategies aimed at preventing tumor escape, such as small molecular weight inhibitors of immunosuppressive molecules, adoptive transfer of TCR transgenic T cells, removal of Tregs, combined with anti-androgen therapy and prostate-specific vaccines, need to be examined further in PC patients.

Matching Content Categories {📚}

Education
Health & Fitness
Science

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We see no obvious way the site makes money.

Some websites aren't about earning revenue; they're built to connect communities or raise awareness. There are numerous motivations behind creating websites. This might be one of them. Doi.org might be cashing in, but we can't detect the method they're using.

Keywords {🔍}

cancer, google, scholar, pubmed, prostate, cas, article, cells, tumor, res, expression, patients, immunotherapy, cell, dendritic, immunol, urol, human, clin, immune, escape, nitric, oxide, antigen, immunother, interleukin, miller, immunity, carcinoma, synthase, huland, shurin, privacy, cookies, content, pisa, therapy, access, int, vaccination, clinical, factor, gene, urology, lymphocytes, prostatic, liu, growth, regulation, wang,

Topics {✒️}

flt3-ligand/cd40-ligand immunotherapy month download article/chapter article cancer immunology signal-transducing zeta chains transforming growth factor-beta1 hormone-refractory prostate cancer fas/fas ligand interactions tumor-host immune interactions tumor-induced immune dysfunction antigen-loaded dendritic cells influence tumor regression/progression tumour-infiltrating lymphocytes t-lymphocyte subset infiltration monocyte-derived dendritic cells blocking t-cell activation prevents long-term survival prostate-specific vaccines full article pdf high-grade prostate cancer cell-based vaccines psa-based vaccines privacy choices/manage cookies tumour escape van de rijn humoral immune responses recombinant human psa dendritic cell immunotherapy prostate cancer progression primary prostate cancer cell receptor dysfunction nitric oxide synthase nitric oxide synthase-2 human solid tumors orthotopic mouse model /ii clinical trials swedish cancer society human prostate cancer situ gene therapy fas-mediated suicide prostate cancer cells dendritic cell dysfunction transgenic mouse model beta-2 microglobulin expression tolerogenic dendritic cells natural killer cells advanced prostate cancer prostate cancer antigens preventing tumor escape miller & pavel pisa defective antigen processing

Questions {❓}

Antony PA, Restifo NP (2002) Do CD4+ CD25+ immunoregulatory T cells hinder tumor immunotherapy?
Lutz MB, Schuler G (2002) Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity?
Pawelec G (2004) Tumour escape: antitumour effectors too much of a good thing?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Tumor escape mechanisms in prostate cancer
         description:Numerous immunotherapy trials have been carried out in prostate cancer (PC) patients, with induction of antigen-specific T cells in some cases. Despite this capability, limited success is seen in terms of tumor regression or survival. In this review, we discuss the evidence for tumor escape strategies that may contribute to vaccine failure in the setting of PC. These include defects in antigen presentation, production of immunosuppressive substances, induction of T cell death, T cell receptor dysfunction, and the presence of tolerogenic dendritic cells and regulatory T cells inside prostate tumors. It is clear that novel strategies aimed at preventing tumor escape, such as small molecular weight inhibitors of immunosuppressive molecules, adoptive transfer of TCR transgenic T cells, removal of Tregs, combined with anti-androgen therapy and prostate-specific vaccines, need to be examined further in PC patients.
         datePublished:2005-12-16T00:00:00Z
         dateModified:2005-12-16T00:00:00Z
         pageStart:81
         pageEnd:87
         sameAs:https://doi.org/10.1007/s00262-005-0110-x
         keywords:
            Prostate cancer
            Immunotherapy
            T cell
            Immune
            Escape
            Tumor
            Oncology
            Immunology
            Cancer Research
         image:
         isPartOf:
            name:Cancer Immunology, Immunotherapy
            issn:
               1432-0851
               0340-7004
            volumeNumber:56
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Ashley M. Miller
               affiliation:
                     name:Karolinska Institute
                     address:
                        name:Immune and Gene Therapy Laboratory, Cancer Centre Karolinska, Karolinska Institute, Stockholm, Sweden
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Pavel Pisa
               affiliation:
                     name:Karolinska Institute
                     address:
                        name:Immune and Gene Therapy Laboratory, Cancer Centre Karolinska, Karolinska Institute, Stockholm, Sweden
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Tumor escape mechanisms in prostate cancer
      description:Numerous immunotherapy trials have been carried out in prostate cancer (PC) patients, with induction of antigen-specific T cells in some cases. Despite this capability, limited success is seen in terms of tumor regression or survival. In this review, we discuss the evidence for tumor escape strategies that may contribute to vaccine failure in the setting of PC. These include defects in antigen presentation, production of immunosuppressive substances, induction of T cell death, T cell receptor dysfunction, and the presence of tolerogenic dendritic cells and regulatory T cells inside prostate tumors. It is clear that novel strategies aimed at preventing tumor escape, such as small molecular weight inhibitors of immunosuppressive molecules, adoptive transfer of TCR transgenic T cells, removal of Tregs, combined with anti-androgen therapy and prostate-specific vaccines, need to be examined further in PC patients.
      datePublished:2005-12-16T00:00:00Z
      dateModified:2005-12-16T00:00:00Z
      pageStart:81
      pageEnd:87
      sameAs:https://doi.org/10.1007/s00262-005-0110-x
      keywords:
         Prostate cancer
         Immunotherapy
         T cell
         Immune
         Escape
         Tumor
         Oncology
         Immunology
         Cancer Research
      image:
      isPartOf:
         name:Cancer Immunology, Immunotherapy
         issn:
            1432-0851
            0340-7004
         volumeNumber:56
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Ashley M. Miller
            affiliation:
                  name:Karolinska Institute
                  address:
                     name:Immune and Gene Therapy Laboratory, Cancer Centre Karolinska, Karolinska Institute, Stockholm, Sweden
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Pavel Pisa
            affiliation:
                  name:Karolinska Institute
                  address:
                     name:Immune and Gene Therapy Laboratory, Cancer Centre Karolinska, Karolinska Institute, Stockholm, Sweden
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Immunology, Immunotherapy
      issn:
         1432-0851
         0340-7004
      volumeNumber:56
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Karolinska Institute
      address:
         name:Immune and Gene Therapy Laboratory, Cancer Centre Karolinska, Karolinska Institute, Stockholm, Sweden
         type:PostalAddress
      name:Karolinska Institute
      address:
         name:Immune and Gene Therapy Laboratory, Cancer Centre Karolinska, Karolinska Institute, Stockholm, Sweden
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Ashley M. Miller
      affiliation:
            name:Karolinska Institute
            address:
               name:Immune and Gene Therapy Laboratory, Cancer Centre Karolinska, Karolinska Institute, Stockholm, Sweden
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Pavel Pisa
      affiliation:
            name:Karolinska Institute
            address:
               name:Immune and Gene Therapy Laboratory, Cancer Centre Karolinska, Karolinska Institute, Stockholm, Sweden
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Immune and Gene Therapy Laboratory, Cancer Centre Karolinska, Karolinska Institute, Stockholm, Sweden
      name:Immune and Gene Therapy Laboratory, Cancer Centre Karolinska, Karolinska Institute, Stockholm, Sweden
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(313)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

Emails and Hosting {✉️}

Mail Servers:

mx.zoho.eu
mx2.zoho.eu
mx3.zoho.eu

Name Servers:

josh.ns.cloudflare.com
zita.ns.cloudflare.com

CDN Services {📦}

Crossref

4.63s.